Boehringer Ingelheim: Cystic Fibrosis trials
The registry lists 11 Cystic Fibrosis studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 6Phase 2 6Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)CompletedNCT05865886Phase 2Results posted
- A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1TerminatedNCT04059094Phase 2Results posted
- BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF SubjectsCompletedNCT02976519Phase 1Results posted
- Tiotropium Bromide in Cystic FibrosisCompletedNCT01179347Phase 3Results posted
- Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic FibrosisCompletedNCT00737100Phase 2Results posted
- A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)Active, not recruitingNCT06962852Phase 1/2
- A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)TerminatedNCT06515002Phase 1/2
- Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) PatientsCompletedNCT02269189Phase 1
- Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) PatientsCompletedNCT02265679Phase 1
- Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis PatientsCompletedNCT02172534Phase 1
- Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric PatientsTerminatedNCT00060801Phase 2